^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CT120 - Results of the glioblastoma multiforme (GBM) cohort of phase 1 trial Ice-CAP (NCT03673787): Preliminary evidence of antitumour activity of Ipatasertib (Ipa) and Atezolizumab (A) in patients (pts) with PTEN loss.
Published date:
03/10/2021
Excerpt:
The Ice-CAP A2 cohort assessed safety, pharmacodynamic, and preliminary clinical activity of Ipa (200mg or 400mg OD) + A (1200mg Q3W) in pts with potentially resectable relapsed WHO Grade IV GBM….7 pts had PTEN loss and/or PTEN mutations. Clinical benefit rate in pts with PTEN aberration was 2/7 (29%): 1 pCR and 1 SD >12wks, both on 400mg Ipa.
Trial ID:
